Alliza Herindar, . (2023) PERBANDINGAN ANTARA PEMBERIAN REMDESIVIR DAN FAVIPIRAVIR TERHADAP LAMA RAWAT INAP PASIEN COVID-19 DI RSUD R SYAMSUDIN SH SUKABUMI. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (156kB) |
|
Text
AWAL.pdf Download (502kB) |
|
Text
BAB 1.pdf Download (196kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (349kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (204kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (344kB) |
|
Text
BAB 5.pdf Download (86kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (200kB) |
|
Text
DAFTAR RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (209kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (2MB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (995kB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (587kB) |
Abstract
Coronavirus disease 2019 (COVID-19) is a global public health problem which is estimated to have a severe disease progression and requires hospitalization. Pharmacological therapy, remdesivir and favipiravir are antiviral drugs that are recommended in the guidelines for the management of COVID-19 in Indonesia. Pharmacological therapy aims to improve the clinical inpatients whose success can be measured by the duration of hospitalization. The purpose of this study was to find out the comparison between the administration of remdesivir and favipiravir on the length of stay of COVID-19 patients. This study used a cross-sectional design with a sample of 42 medical records of confirmed COVID-19 patients who fit the criteria and were selected using a purposive sampling technique. Data were analyzed using the T independent test. The results showed that there was a significant difference between the administration of remdesivir and favipiravir on the length of stay of COVID-19 patients (p <0.05). The average length of stay of COVID-19 patients who received favipiravir was shorter, which was 7.33 ± 1.983 (mean ± SD) compared to patients who received remdesivir, 9.29 ± 1.927 (mean ± SD). Based on the result, favipiravir is more effective than remdesivir in reducing the length of stay of COVID-19 patients, so favipiravir therapy can be chosen for patients who fit the criteria of this study to reduce the length of stay of COVID-19 patients.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | No. Panggil 1910211006 Pembimbing 1 : Hany Yusmaini Pembimbing 2 : Cut Fauziah Penguji : Boenga Nurcita |
| Uncontrolled Keywords: | COVID-19, Favipiravir, Length of Stay, Remdesivir |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
| Depositing User: | Alliza Herindar |
| Date Deposited: | 16 Mar 2023 10:50 |
| Last Modified: | 16 Mar 2023 10:50 |
| URI: | http://repository.upnvj.ac.id/id/eprint/22900 |
Actions (login required)
 |
View Item |